Orphan Drug Designation Granted for First-in-Class Drug for Metastatic Brain Cancer

Diffusion Pharmaceuticals announced that trans sodium crocetinate (TSC) has been granted an Orphan Drug designation by the FDA for the treatment of metastatic brain cancer. TSC is a proprietary, first-in-class small molecule belonging to the novel oxygen diffusion-enhancing compound family of drugs.

The FDA has previously granted Diffusion Pharmaceuticals an Orphan Drug designation for the use of TSC in the treatment of the primary brain cancer (glioblastoma multiforme or GBM). A Phase 2 clinical trial testing TSC in newly diagnosed GBM patients is now enrolling patients at twenty major cancer centers around the U.S. A Phase 2 clinical study testing TSC in brain metastases is currently being planned in cooperation with these centers.

For more information call (434) 220-0718 or visit www.diffusionpharma.com.